| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_19c636ca82c5706032587b294dc5778c |
| classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2039-543
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2039-54
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2770-16034
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2770-16023
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2039-70
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2039-55572
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2039-5258 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K39-125
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P9-14
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P1-04
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P37-04
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N7-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K39-42
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K39-39
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P31-14
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K39-12
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K16-10 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K39-42
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K39-12 |
| filingDate |
2007-09-28-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate |
2016-07-19-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_f87d6b7ae11d1ea877d68b324d594c49
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_ce964ea4830480683c367aa8bf8d1614
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_aa8516ec7c6579c32d4d491338cc707f
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_817729585906819ffbc2cc034f7334f0 |
| publicationDate |
2016-07-19-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
ES-2577833-T3 |
| titleOfInvention |
Norovirus vaccine formulations |
| abstract |
A composition comprising at least one norovirus antigen and at least one adjuvant; wherein the adjuvant is selected from the group consisting of an adjuvant that is an aluminum salt and an adjuvant that is a toll-like receptor agonist (TLR); wherein the composition is formulated as a liquid; and wherein the content of at least one norovirus antigen in the composition is from about 1 µg to about 200 µg per dose. |
| priorityDate |
2006-09-29-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |